Impact of OSA on Biological Markers in Morbid Obesity and Metabolic Syndrome
Por:
Salord, N, Gasa, M, Mayos, M, Fortuna-Gutierrez, AM, Montserrat, JM, Sanchez-de-la-Torre, M, Barcelo, A, Barbe, F, Vilarrasa, N, Monasterio, C
Publicada:
1 ene 2014
Resumen:
Background and Objective: There is compelling evidence that obstructive sleep apnoea (OSA) can affect metabolic syndrome (MetS) and cardiovascular risk, but the intermediate mechanisms through which it occurs have not been well defined. We explored the impact of OSA in morbidly obese patients with MetS on adipokines, pro-inflammatory markers, endothelial dysfunction, and atherosclerosis markers.
Methods: We included 52 morbidly obese patients in an observational study matched for age, gender and central obesity in 3 groups (OSA-MetS, Non-OSA-MetS, and Non OSA-non-MetS). Anthropometrical, blood pressure, and fasting blood measurements were obtained the morning after an overnight polysomnography. VEGF, soluble CD40 ligand (sCD40L), TNF-alpha, IL-6, leptin, adiponectin, and chemerin were determined in serum by ELISA. OSA was defined as apnea/hypopnea index >= 15 and MetS by NCEP-ATP III.
Results: Cases and control subjects did not differ in age, BMI, waist circumference, and gender (43 +/- 10 years, 46 +/- 5 kg/m(2), 128 +/- 10 cm, 71% females). The cases had severe OSA with 47 (32-66) events/h, time spent < 90% SpO(2) 7% (5%-31%). All groups presented similar serum cytokines, adipokines, VEGF, and sCD40L levels.
Conclusions: In a morbidly obese population with established MetS, the presence of OSA did not determine any differences in the studied mediators when matched by central obesity. Morbidly obese NonOSA-NonMetS had a similar inflammatory, adipokine VEGF, and sCD40L profile as those with established MetS, with or without OSA. Obesity itself could overwhelm the effect of sleep apnea and MetS in the studied biomarkers.
Filiaciones:
Salord, N:
Hosp Univ Bellvitge, Dept Resp Med, Sleep Unit, Lhospitalet De Llobregat 08907, Spain
Bellvitge Biomed Res Inst IDIBELL, Sect Resp Med, Lhospitalet De Llobregat, Spain
Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Gasa, M:
Hosp Univ Bellvitge, Dept Resp Med, Sleep Unit, Lhospitalet De Llobregat 08907, Spain
Bellvitge Biomed Res Inst IDIBELL, Sect Resp Med, Lhospitalet De Llobregat, Spain
Mayos, M:
Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Santa Creu & Sant Pau, Dept Resp Med, Sleep Unit, Barcelona, Spain
Fortuna-Gutierrez, AM:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Santa Creu & Sant Pau, Dept Resp Med, Sleep Unit, Barcelona, Spain
Montserrat, JM:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Clin Barcelona, Dept Resp Med, Sleep Unit, Barcelona, Spain
Sanchez-de-la-Torre, M:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Arnau Vilanova, Resp Dis Res Unit, Irb Lleida Lleida, Spain
Barcelo, A:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Univ Son Espases, Clin Anal Serv, Palma De Mallorca, Spain
Barbe, F:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Hosp Univ Son Espases, Clin Anal Serv, Palma De Mallorca, Spain
Vilarrasa, N:
Hosp Univ Bellvitge, Dept Endocrinol & Nutr, Lhospitalet De Llobregat, Spain
CIBER Diabet & Enfermedades Metab Asociadas CIBER, Barcelona, Spain
Monasterio, C:
Hosp Univ Bellvitge, Dept Resp Med, Sleep Unit, Lhospitalet De Llobregat 08907, Spain
Bellvitge Biomed Res Inst IDIBELL, Sect Resp Med, Lhospitalet De Llobregat, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain
Green Published
|